Table 2.
Compound | REC10 (a) | Relative Potency (b) |
---|---|---|
TCDD | 1.0 × 10−12 | 1 |
L-Tryptophan | N.E. (c) | <3.3 × 10−9 |
L-Kynurenine | 7.0 × 10−7 | 1.4 × 10−6 |
Tryptamine | 6.3 × 10−5 | 1.6 × 10−8 |
3-Methylindole | 7.8 × 10−5 | 1.3 × 10−8 |
Xanthurenic acid | 1.2 × 10−4 | 8.3 × 10−9 |
5-Hydroxyindole-3-acetic acid | 1.5 × 10−4 | 6.7 × 10−9 |
Indole-3-carboxylic acid | N.E. | <3.3 × 10−9 |
Indole-3-carboxaldehyde | N.E. | <3.3 × 10−9 |
Indole-3-acetamide | N.E. | <3.3 × 10−9 |
3-Indoleacetic acid | N.E. | <3.3 × 10−9 |
3-Indolepropionic acid | N.E. | <3.3 × 10−9 |
Indole | N.E. | <3.3 × 10−9 |
Kynurenic acid | N.E. | <3.3 × 10−9 |
Anthranilic acid | N.E. | <3.3 × 10−9 |
Pyridine-2-carboxylic acid | N.E. | <3.3 × 10−9 |
2,3-Pyridinedicarboxylic acid | N.E. | <3.3 × 10−9 |
(a) 10% relative effective concentration (M): the concentration of the test compound showing 10% of the agonistic activity induced by 1 × 10−10 M TCDD. (b) Relative potency is expressed as a ratio of REC10 of TCDD to that of a test compound; i.e., the relative potency of TCDD is arbitrarily set at 1. (c) No effect (REC10 > 3 × 10−4 M).